Marketing-authorisation holder
Tanvex BioPharma USA, Inc.
3 medicines in 2 countries, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| NYPOZI480 mcg / 0.8 ml · Solution | Filgrastim | Canada | Marketed | 2024 |
| NYPOZI300mcg/0.5ml | 480mcg/0.8ml · Injectable | Filgrastim | United States | Marketed | 2024 |
| NYPOZI300 mcg / 0.5 ml · Solution | Filgrastim | Canada | Marketed | 2024 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 2 | 2 | 0 | CompaniesAll medicines |
| United States | 1 | 1 | 0 | CompaniesAll medicines |
Therapeutic areas
The ATC groups most of its medicines belong to, largest first.
- ImmunostimulantsAntineoplastic and immunomodulating agents · ATC L03A
Top substances
The active substances in most of its medicines.
Names in the registers
How the registers spell it, normalised: legal forms, accents and capitals removed.
- tanvex biopharma
- tanvex biopharma usa inc
Sources and licences
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
At a glance
- Type
- Marketing-authorisation holder
- Medicines
- 3
- Countries
- 2
- Roles
- Authorisation holder